These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 22388825)
1. [Indications for apheresis in kidney transplant recipients: apheresis in the hyperimmune patient]. Busnach G; Di Leo L G Ital Nefrol; 2012; 29 Suppl 54():S22-6. PubMed ID: 22388825 [TBL] [Abstract][Full Text] [Related]
2. Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection. Hirai T; Kohei N; Omoto K; Ishida H; Tanabe K Transpl Int; 2012 Sep; 25(9):925-34. PubMed ID: 22764746 [TBL] [Abstract][Full Text] [Related]
3. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis. Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165 [TBL] [Abstract][Full Text] [Related]
4. Alloantibodies and the outcome of cadaver kidney allografts. Vasilescu ER; Ho EK; Colovai AI; Vlad G; Foca-Rodi A; Markowitz GS; D'Agati V; Hardy MA; Ratner LE; Suciu-Foca N Hum Immunol; 2006 Aug; 67(8):597-604. PubMed ID: 16916655 [TBL] [Abstract][Full Text] [Related]
5. The role of therapeutic apheresis in high immunologic risk renal transplantation: a review of current trends. Sanoff SL; Balogun RA; Lobo PL Semin Dial; 2012; 25(2):193-200. PubMed ID: 22321316 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates. Rostaing L; Congy N; Aarnink A; Maggioni S; Allal A; Sallusto F; Game X; Kamar N Exp Clin Transplant; 2015 Apr; 13 Suppl 1():201-6. PubMed ID: 25894155 [TBL] [Abstract][Full Text] [Related]
7. Successful transplantation across positive B-cell cross-match in deceased donor renal transplants. Goh A; Oei E; Vathsala A Transplant Proc; 2012 Jan; 44(1):193-9. PubMed ID: 22310613 [TBL] [Abstract][Full Text] [Related]
8. Posttransplant immunosuppression in highly sensitized patients. Akalin E Contrib Nephrol; 2009; 162():27-34. PubMed ID: 19001811 [TBL] [Abstract][Full Text] [Related]
9. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Vlad G; Ho EK; Vasilescu ER; Colovai AI; Stokes MB; Markowitz GS; D'Agati VD; Cohen DJ; Ratner LE; Suciu-Foca N Hum Immunol; 2009 Aug; 70(8):589-94. PubMed ID: 19375470 [TBL] [Abstract][Full Text] [Related]
10. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Reinsmoen NL; Lai CH; Vo A; Cao K; Ong G; Naim M; Wang Q; Jordan SC Transplantation; 2008 Sep; 86(6):820-5. PubMed ID: 18813107 [TBL] [Abstract][Full Text] [Related]
11. The strength of donor-specific antibody is a more reliable predictor of antibody-mediated rejection than flow cytometry crossmatch analysis in desensitized kidney recipients. Mujtaba MA; Goggins W; Lobashevsky A; Sharfuddin AA; Yaqub MS; Mishler DP; Brahmi Z; Higgins N; Milgrom MM; Diez A; Taber T Clin Transplant; 2011; 25(1):E96-102. PubMed ID: 20977497 [TBL] [Abstract][Full Text] [Related]